Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.

J Bone Oncol · 2018 · PMC5709351 · PMID 29204337

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

did not reach statistical significancep = 0.11not close (p > 0.1)

Having a prior SRE trended towards an increased risk for having a future SRE, but this did not reach statistical significance (hazard ratio = 2.43, 95% CI = 0.832 7.17, p = 0.11).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.